Purpose: To compare safety, tolerability and intraocular pressure (IOP)-lowering efficacy of pattern scanning laser trabeculoplasty (PSLT) with selective laser trabeculoplasty (SLT) in fellow eyes of untreated patients with glaucoma. Design: Randomized controlled trial. Participants: Twenty-nine patients (58 eyes) with primary and secondary open angle glaucoma (OAG) were randomized to undergo PSLT or SLT in each eye. Methods: Pattern scanning laser trabeculoplasty was performed using the Pascal laser (Pascal Streamline 577; Topcon Inc., Tokyo, Japan). Patients' comfort level to treatment was assessed using a visual analogue scale (VAS). Follow-up visits were at week 1, month 1, 3 and 6. Success was defined as IOP reduction ≥20%. Main Outcome Measures: Safety, tolerability and IOP reduction. Results: The mean age of patients was 54.1 AE 15.5 years. Baseline IOP was similar between both groups (PSLT, 17.3 AE 4.0 mmHg; SLT, 16.8 AE 3.6 mmHg, p > 0.05). In the PSLT group, the mean IOP at 1, 3 and 6 months was 14.2 AE 3.5, 13.9 AE 2.6 and 14.0 AE 2.7 mmHg, respectively. In the SLT group, the mean IOP at 1, 3 and 6 months was 14.4 AE 4.1, 13.7 AE 3.2 and 13.7 AE 3.1 mmHg, respectively. The IOP reduction in the PSLT group was greater than the SLT group at 1 month (p < 0.01) and 3 months (p < 0.01). VAS score was better in PSLT eyes: 23.9 AE 20.5 (range, 0-82) than in SLT eyes: 50.4 AE 25.3 (range, 0-98) (p < 0.001). No serious adverse events were recorded. Conclusion: Both laser modalities had similar safety and efficacy profiles while PSLT was better tolerated by patients.
Introduction
Elevated IOP is the only treatable risk factor for glaucoma (Weinreb et al. 2014) . Argon laser trabeculoplasty (ALT) with a wavelength (k) of 488-514 nm was described in the 1970s as a treatment option for glaucoma (Worthen & Wickham 1973; Wise & Witter 1979) . ALT improves the outflow of aqueous by photocoagulation of the small (50 lm) spots in trabecular meshwork (TM), thereby lowering IOP. Selective laser trabeculoplasty (SLT) with a Q-switched (3 ns), frequency-doubled Nd:YAG laser (k = 532) nm was introduced two decades later as an alternative to ALT (Latina et al. 1998 ). Selective laser trabeculoplasty was developed to selectively target pigmented TM cells without coagulative damage to the TM architecture or non-pigmented cells. It has been shown to be comparable to ALT in safety and efficacy (Juzych et al. 2004; Damji et al. 2006; Liu & Birt 2012; Wang et al. 2013) . At present, SLT has mostly replaced the ALT due to its ease of use and possibility for repeat treatments. Selective laser trabeculoplasty has been demonstrated to be effective as primary treatment for open angle glaucoma and can be an effective adjunct in the early treatment of glaucoma (Samples et al. 2011) .
Recently, a computer-guided pattern scanning laser (PASCAL, k = 532 nm) has been described for use in trabeculoplasty (Turati et al. 2010) . The treatment begins with titration to a barely visible lesion, after which the pulse energy is reduced by half to produce subvisible treatment on TM. To ensure complete coverage of TM and proper alignment of the sequence of patterns despite the lack of visible burns, a special treatment algorithm, called PSLT, has been developed (Turati et al. 2010) . The arc-shaped patterns are automatically rotated after each application by the angle matching the angle of arc covered by a single pattern on TM (11.25°). This ensures that consecutive patterns abut without overlaps or significant gaps. Unlike ALT, the IOP-lowering effect of PSLT was achieved without visible damage to TM . Like SLT, it provides uniform coverage of TM, but with some notable differences in the treatment parameters. Pattern scanning laser trabeculoplasty has longer pulse duration than SLT: 5 ms versus 3 ns, smaller spot size: 100 lm versus 400 lm and slightly higher pulse energy: approximately 3 mJ compared to approximately 1 mJ generally used in SLT.
Two previous studies have evaluated the safety and efficacy of PSLT in glaucoma eyes (Turati et al. 2010; Barbu et al. 2014) . However, to date, no randomized controlled trial has been conducted to compare PSLT to SLT. Thus, the aim of this study was to prospectively investigate the safety, tolerability and efficacy of PSLT compared to SLT.
Patients and Methods

Study design
This trial was conducted at the Glaucoma sector, Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland, between 1 May 2014 and June 2015 and was approved by the institutional review board of the University of Geneva. All patients provided written, informed consent prior to study inclusion. The study was registered on ClinicalTrials.gov (NCT02231515).
Study population
Eligible patients were aged 18 years or older with a diagnosis of primary or secondary OAG. Eyes were classified as glaucomatous if they had repeatable (two consecutive) abnormal standard automated perimetry test results (Octopus, Haag Streit, Koeniz, Switzerland) in the presence of abnormal appearing optic discs (presence of neuroretinal rim thinning or localized or diffuse Retinal nerve fiber layer defects indicative of glaucoma) by slit-lamp assessment or SD-OCT. Visual field exams required reliability indices better than 15%. Gonioscopy was performed on all eyes prior to study inclusion.
Gonioscopically open angles were a requirement for study inclusion. Both eyes of each patient had to be eligible and were enrolled in the study. Patients were selected from the authors' glaucoma clinics. Indications for laser procedure were those followed by the authors' usual clinical practice. In essence, these include medically uncontrolled IOP and/or intolerance to medical IOP treatment. Patients with previous laser trabeculoplasty, laser iridotomy, laser iridoplasty or incisional glaucoma surgery were excluded. Included individuals were either newly diagnosed and untreated glaucoma patients or patients who underwent a 4-week washout period prior to the first study visit (Stewart et al. 2001) .
Randomization was performed using sequentially numbered sealed envelopes, prepared by a study coordinator who was not involved in other aspects of the study, to assign each eye to PSLT or SLT. Patients were informed that each eye would be treated with a different laser device and were briefly informed about the general characteristics of each. No mention was made of any laser being potentially superior in safety, tolerability or comfort, as the study's null hypothesis was equivalence between the two lasers. Patients were masked as to the treatment allocation. If patients requested this information, they were informed at month 3.
Laser treatment procedure
All eyes received a single session of 360-degree laser treatment. Pattern scanning laser trabeculoplasty was performed using the Pascal laser (Pascal Streamline 577; Topcon Inc., Tokyo, Japan). A custom-made PSLT gonioscopy lens (Ocular Latina 1X Indexing PSLT Lens; Ocular Instruments, Bellevue, WA, USA) was used to project and align the laser patterns onto the TM. Laser power was titrated by placing a single laser spot (100 lm diameter) in the inferior quadrant at 10-ms exposure duration. In all cases, a starting power level of 500 mW was chosen and power was reduced or increased until a barely visible lesion (light blanching of TM) was achieved. In a majority of eyes, some degree of pigmentation was visible in the inferior chamber angle (where titration was performed). In the absence of pigmentation, PSLT procedure was performed with 500 mW. After titration, power was maintained but the pulse duration was automatically reduced to 5 ms to produce subvisible lesions. The 360°treat-ment of TM was administered in 32 steps, where each pattern is composed of 36 spots: three rows of 13 spots each (1152 in total), with zero spacing between the adjacent spots.
Sellective laser trabeculoplasty (SLT) treatment was performed using the Ellex Tango laser (Ellex Medical Lasers Ltd., Adelaide, Australia). Starting power was set at 0.6 mJ and titrated to produce cavitation bubbles, after which it was reduced in 0.1 mJ increments until only occasional bubbles were observed. In all cases, a total of 100-110 non-overlapping spots were applied at energy levels ranging from 0.4 to 1.0 mJ per pulse. All laser procedures were performed by the same surgeon (K.M). The fellow eye was treated 1 week after the first eye. Time of laser treatment was defined as the time the gonioscopy lens was applied on the eye until the end of treatment.
Patients were pretreated with two drops of pilocarpine 2%. A drop of apraclonidine 1% was instilled in all treated eyes postlaser. Patients were prescribed keratolac tromethamine 0.5%, one drop four times daily for 4 days and one drop of brimonidine two times daily for 4 days. Patients were assessed 1 hr after laser treatment. At this stage, they were asked to score their subjective comfort level using the VAS with values ranging from 0 (No Discomfort) to 100 (Very Severe Discomfort), the number corresponding to the distance in millimetres of the participant's mark on the VAS line from the left end (Collins et al. 1997) . Follow-up visits were at 1 week, 1 month, 3 months and 6 months. All IOP measurements consisted of three readings using Goldmann applanation tonometry, and the average was used in data analysis. Intraocular pressure measurements were performed by experienced residents who were not masked to the laser procedure but were uninvolved in the study. Tonometers were calibrated every 3 months.
Statistical analysis
Data are expressed as mean AE standard deviation (SD) or interquartile range (IQR), where appropriate. Categorical variables are described in terms of frequencies and percentages. Data were analysed statistically using a twotailed unpaired t-test, chi-squared test, Mann-Whitney U-test, repeatedmeasures analysis of variance. Kaplan-Meier survival analysis with Mantel-Cox log-rank test was used to compare outcomes between groups. Sample size was calculated to have sufficient power (at least 80% and twosided alpha of 0.05) to detect to reject the null hypothesis of an intergroup IOP difference of 3 mmHg with a SD of 3.5 mmHg at 1 month. All hypothesis testing was two-sided, at two-sided a = 0.05. All analyses were conducted using SAS Version 9.2 (SAS Inc, Cary, NC, USA).
Primary outcome measure was absolute change in IOP from baseline. Baseline IOP was the IOP measured after patient inclusion into the study. Treatment success was defined as an IOP reduction ≥20% without ocular hypotensive medications. Finally, patient-reported comfort level using the VAS was compared between the two groups. Secondary outcomes were safety and patient comfort. All eyes that were randomized were analysed in an intent-to-treat analysis.
Results
A total of 58 eyes of 29 patients with glaucoma (72.4% male) were included in the study (56% right eyes). Mean age of patients was 54.1 AE 15.5 years (range, 23-73). All baseline characteristics were similarly distributed in the two groups (Table 1) . Mean follow-up time was 6.1 AE 2.5 months for patients in the PSLT group and 6.5 AE 2.9 months (p = 0.68) for patients in the SLT group, with a range of 3-12 months.
Pattern scanning laser trabeculoplasty was performed with the standard 1152 laser spots (32 patterns of 36 spots in each), with a mean titration power of 559.3 AE 17.2 mW (range 525-600 mW). Scanning laser trabeculoplasty treatment was performed with a mean of 84.5 AE 18.6 laser spots (range, 45-105) and a mean energy of 1.1 AE 0.3 mJ (range 0.7-1.6 mJ). In all PSLT patients, 360°of angle were treated in a single session. In one SLT eye, only 180°could be treated.
Duration of laser treatment was 3.8 AE 0.5 min for PSLT and 5.3 AE 0.8 min for SLT (p < 0.001).
Complications included mild conjunctival hyperaemia and anterior chamber flare within 24 hr postoperatively in 10 PSLT and 11 SLT eyes. There were no serious adverse events in both groups. One week after SLT, one patient had an IOP increase of 15 mmHg, which remained uncontrolled on medical therapy and required filtering surgery.
Patient comfort as assessed by the VAS scale was 23.9 AE 20.5 (range, 0-82) in PSLT eyes and 50.4 AE 25.3 (range, 0-98) in SLT eyes (p < 0.001, Wilcoxon signed rank), indicating better tolerability for PSLT.
Baseline IOP was similar between both groups (PSLT, 17.3 AE 4.0 mmHg; SLT, 16.8 AE 3.6 mmHg, p = 0.48). In the PSLT group, the mean IOP at 1 week, 1, 3 and 6 months was 16.1 AE 4.1, 14.2 AE 3.5, 13.9 AE 2.6 and 14.0 AE 2.7 mmHg, respectively. In the SLT group, the mean IOP at 1 week, 1, 3 and 6 months was 16.0 AE 4.4, 14.4 AE 4.1, 13.7 AE 3.2 and 13.7 AE 3.1 mmHg, respectively (Fig. 1) . In both groups, the effect of IOP reduction from baseline was statistically significant at all time-points (p < 0.01). The percentage of IOP reduction in the PSLT group was greater than the SLT group at 1 month (p < 0.01) and 3 months (p < 0.01). At 6 months, there were no differences between the PSLT and SLT groups in the absolute mean reduction of IOP (3.3 versus 3.1 mmHg, respectively; p = 0.78) or in the percentage of reduction in IOP (19.1% versus 18.5%, respectively; p = 0.52). Complete success was 37% (PSLT) and 32% (SLT) at 3 months (p = 0.83) and 37% (PSLT) and 26% (SLT) at 6 months (p = 0.09). 
Discussion
In this study, we compared the standard SLT laser to the PASCAL laser with the new PSLT software. Our results showed that over 6 months' duration, the PSLT laser was similar to the SLT laser in terms of efficacy. Both lasers had a similar safety profile, while PSLT was perceived as more comfortable by patients. In both groups, and in accordance with published literature, early complications were transient and self-limiting. A prospective pilot study using an earlier model of the PSLT software in PASCAL laser with 532 nm (green) wavelength, included 47 eyes of 25 patients (Turati et al. 2010 ). The average IOP drop was from 21.9 AE 4.1 to 15.5 AE 2.7 mmHg at 6 months of follow-up. However, 17 eyes were excluded because of either having a viral conjunctivitis or requiring additional antiglaucoma therapy for IOP lowering after the procedure. Twenty of the 30 eyes (67%) achieved an average IOP reduction of 24%. Barbu et al. (Barbu et al. 2014 ) demonstrated reduction of mean IOP from 20.2 AE 1.1 to 15.6 AE 0.8 mmHg (23%) (p < 0.001) in 20 eyes of 20 patients 8 weeks after PSLT treatment (Barbu et al. 2014) . Retrospective analysis showed no statistical difference in IOP reduction compared with ALT (p = 0.26)The higher comfort level of PSLT may be related to the shorter total duration of the treatment, which provides a potential advantage over SLT.
Success rates and IOP reduction of SLT in the present study were comparable to those reported in published literature, although at the lower range (Samples et al. 2011; ). On average, both laser treatments lowered IOP by 19% (from mean of 17.1-13.9 mmHg) in this study after 6 months. The low baseline IOP in this study is a likely reason for the relatively modest IOP-lowering effect. It has been shown that laser trabeculoplasty exhibits stronger efficacy at higher baseline IOP (Hodge et al. 2005; Mao et al. 2008; Tzimis et al. 2011; Pillunat et al. 2016 ). In the early manifest glaucoma trial (EMGT), IOP was reduced from 18.1 AE 3.9 mmHg (on betaxolol) by 2.8 AE 3.9 mmHg (12.6 AE 20.5%) 3 months after ALT. (Heijl et al. 2011 ) Importantly, it demonstrated the effect of prelaser IOP on the efficacy of laser treatment. The authors found that each 3-mmHg higher IOP before ALT was associated with an additional IOP reduction of 2 mmHg. Recently, Pillunat et al., (Pillunat et al. 2016) in a large prospective trial showed that preoperative IOP was the only predictive parameter for IOP reduction after SLT. They also suggested that SLT may not work for baseline IOP levels below 14 mmHg. Although we did not categorize our POAG patients with low IOP as normal-tension glaucoma (NTG), (Sommer 2011) many of them would have been classified as such using commonly used cut-offs. Studies that included patients with NTG have report efficacy rates of 19.7% (6 months), (Lee et al. 2015) , 14.7% (10 months), (El et al. 2010 ) and 14.6% (at 36 months) (Nitta et al. 2013) .
Most previous studies evaluate the efficacy of laser trabeculoplasty in patients who are also using glaucoma drops, which can potentially interfere with the laser effect. The fact that patients in this study underwent medication washout before treatment and remained untreated up to 6 months constitutes a strength. A further strength of our study was the fact that both eyes of patients were included and randomized to the type of laser treatment, eliminating selection bias. We can, however, not exclude a potential cross-over effect from one eye on the fellow one, as has been previously described (Onakoya et al. 2015 ). An interesting finding of our study was the better tolerability of PSLT compared to SLT. We do not have an explanation for this finding; however, shorter treatment duration and the different laser settings may have contributed to this. Patients were masked to the laser type at the time of VAS assessment. There is no indication; therefore, that patients' VAS scoring could have been biased towards either treatment type.
Other lasers for trabeculoplasty have been described recently. Melamed et al. evaluated trabeculoplasty with a titanium sapphire laser (TSLT) (Goldenfeld et al. 2009 ), which emits 790 nm wavelength in pulses ranging from 5 to 10 ms. This near-infrared radiation is thought to allow deeper penetration into the juxtacanalicular meshwork and the inner wall of Schlemm's canal. The laser energy is then selectively absorbed by pigmented phagocytic cells. They conducted a 15-month pilot study with 37 subjects comparing TSLT versus ALT, and demonstrated that a mean IOP reduction after TSLT was 8 mmHg (32%), while the ALT group achieved a 6.5 mmHg (25%) IOP reduction. There was no statistical difference between the two groups. Kaplowitz et al. (2016) reported a 35% IOP reduction 2 years after TSLT treatment.
Although the mechanism of action of PSLT is not clear, similar to SLT, the lack of coagulative damage and tissue scarring suggests possible reactions at the cellular level. Pattern scanning laser trabeculoplasty has much shorter pulse duration (5 ms) compared with ALT (100 ms), thereby reducing the thermal diffusion from the treatment area. To compensate for the lack of thermal spread and to provide a uniform coverage of the TM, PSLT applies approximately 10 times more spots than ALT. In terms of the total treatment area, the 400 lm spot in SLT covers 16 times larger area than a 100 lm spot in PSLT, and therefore the total treated area with 100 spots in SLT is by about 30% larger than with 1152 spots in PSLT. demonstrated that subvisible exposures (250-350 mW power) in PSLT resulted in thinning of the uveal meshwork and denudation of trabecular endothelial cells in cat eyes. Compared to ALT-treated eyes, there was substantially less thermal damage and trabecular beams were not disrupted. However, they observed appearance of membranous structures partially covering the TM approximately 2 months after the treatment.
In summary, PSLT seems to be as safe and effective as SLT in patients with OAG. Longer follow-up is required to assess longevity of the IOP-lowering effect. We look forward to studies evaluating the effect of repeated treatment of PSLT versus SLT. Our results suggest that PSLT may be a useful primary therapeutic modality in patients with glaucoma.
